{"id":1008,"date":"2024-11-23T08:19:01","date_gmt":"2024-11-23T08:19:01","guid":{"rendered":"https:\/\/one-peptides.com\/product\/cjc-1295-with-dac-5mg\/"},"modified":"2026-10-09T07:57:50","modified_gmt":"2026-10-09T07:57:50","slug":"cjc-1295-with-dac-5mg","status":"publish","type":"product","link":"https:\/\/one-peptides.com\/de\/produkt\/cjc-1295-with-dac-5mg\/","title":{"rendered":"CJC-1295 WITH DAC 5 mg"},"content":{"rendered":"

 <\/p>\n

One Peptides CJC-1295 with DAC (CJC-1295 WITH DAC) 5 mg – chemical reagent for laboratory tests<\/strong><\/h2>\n

Research Use Only (RUO). Chemical reagent intended only for laboratory tests. It is not intended for human consumption or diagnostic purposes.<\/span><\/p>\n

Related categories and reagents:<\/strong> In the context of this area of \u200b\u200bresearch, it is also worth comparing growth hormone secretagogues<\/a>, CJC without DAC<\/a> and Ipamorelin<\/a>.<\/p>\n

CJC-1295 with DAC vs the variant without DAC.<\/strong> The peptide core is the same; the difference is the DAC (Drug Affinity Complex) moiety and the resulting approximately 279 g\/mol of mass\u20143,647.28 g\/mol compared with 3,367.9 g\/mol for the variant without DAC. DAC is described in the literature as an element that binds the peptide to serum albumin, which translates into a longer presence of the molecule in the studied system. Selecting a variant for an experiment is therefore a matter of the intended time horizon, not potency.<\/p>\n

CJC-1295 vs ipamorelin.<\/strong> Different classes and different receptors: CJC-1295 is a GHRH analogue described in relation to GHRH-R, while ipamorelin (711.85 g\/mol, a pentapeptide) is an agonist of the ghrelin receptor GHS-R1a. Comparisons of the two in the literature are based on their representing two independent entry points into the growth hormone axis.<\/p>\n

Introduction and research framework<\/strong><\/h2>\n

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide that is a modified analogue of human growth hormone releasing hormone (GHRH), equipped with a unique chemical modification enabling covalent binding to plasma albumin. This innovative modification, developed by ConjuChem Biotechnologies, significantly increases the half-life of the peptide in research models.<\/p>\n

The CJC-1295 peptide from DAC is the subject of intensive scientific research due to its unique pharmacokinetic properties that distinguish it from other GHRH analogues. DAC modification is an example of advanced peptide engineering aimed at optimizing the time profile of biological activity.<\/p>\n

General characteristics of the compound<\/strong><\/h2>\n

CJC-1295 from DAC is a 30-amino acid peptide derived from modified GHRH(1-29), enriched with a maleimidopropionic group (MPA) attached to an additional lysine residue at the C-terminus. The MPA group enables the formation of a covalent thioester bond with cysteine \u200b\u200bresidues of plasma albumins, which in research models leads to a significant extension of the peptide circulation time.<\/p>\n

DAC (Drug Affinity Complex) technology was developed as a method of extending the duration of action of therapeutic peptides. In the case of CJC-1295, after binding to albumin, a complex with a molecular weight of approximately 70 kDa is formed, which is protected against rapid enzymatic degradation and renal elimination.<\/p>\n

The One Peptides CJC-1295 WITH DAC 5 mg material is supplied in the form of a high-purity lyophilized powder, intended for use in advanced biochemical research.<\/p>\n

What is CJC-1295 with DAC?<\/strong><\/h2>\n

CJC-1295 with DAC (also known as DAC:GRF or CJC-1295-MPA) is a synthetic peptide combining:<\/p>\n

    \n
  1. Modified GHRH(1-29) sequence with four amino acid substitutions<\/li>\n
  2. An additional lysine residue at the C-terminus<\/li>\n
  3. A maleimidopropionic group (MPA) attached to this lysine<\/li>\n<\/ol>\n

    DAC (Drug Affinity Complex) technology<\/strong><\/h3>\n

    DAC is a patented technology that involves attaching a reactive maleimide group to a peptide. This group reacts specifically with thiol groups (-SH) of free cysteine \u200b\u200bresidues in albumin, forming a stable covalent bond.<\/p>\n

    Binding mechanism:<\/strong><\/p>\n

    Peptide-MPA + Albumin-SH \u2192 Peptide-MPA-S-Albumin\r\n<\/code><\/pre>\n
    Comparison with the version without DAC<\/strong><\/h3>\n\n\n\n\n\n\n\n\n\n
    Characteristic<\/th>\nCJC-1295 with DAC<\/th>\nCJC-1295 without DAC<\/th>\n<\/tr>\n<\/thead>\n
    Number of amino acids<\/td>\n30<\/td>\n29<\/td>\n<\/tr>\n
    C-terminal modification<\/td>\nLys-MPA<\/td>\nAmidation<\/td>\n<\/tr>\n
    Binding to albumin<\/td>\nCovalent<\/td>\nLack<\/td>\n<\/tr>\n
    Half-life (research)<\/td>\n~8 days<\/td>\n~30 min<\/td>\n<\/tr>\n
    Molar mass<\/td>\n~3647 g\/mol<\/td>\n~3368 g\/mol<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
    Structure and physicochemical properties<\/strong><\/h2>\n
    Amino Acid Sequence<\/strong><\/h3>\n
    CJC-1295 with DAC has the following structure:<\/p>\n
    H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(MPA)-NH2<\/strong><\/p>\n
    Where:<\/p>\n
      \n
    • Positions 1-29: modified GHRH(1-29) identical to CJC-1295 without DAC<\/li>\n
    • Item 30: Lysine with a maleimidopropionic group attached (MPA)<\/li>\n<\/ul>\n
      Amino Acid Modifications (items 1-29)<\/strong><\/h3>\n
        \n
      • Item 2: D-Alanine (protection against DPP-IV)<\/li>\n
      • Item 8: Glutamine (preventing deamidation)<\/li>\n
      • Item 15: Alanine (structure stabilization)<\/li>\n
      • Item 27: Leucine (oxidation protection)<\/li>\n<\/ul>\n
        Physicochemical properties<\/strong><\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n
        Parameter<\/th>\nValue<\/th>\n<\/tr>\n<\/thead>\n
        Summary formula<\/td>\nC165H269N47O46<\/td>\n<\/tr>\n
        Molar mass<\/td>\n~3647.28 g\/mol<\/td>\n<\/tr>\n
        CAS number<\/td>\n863288-34-0 (base peptide)<\/td>\n<\/tr>\n
        Number of amino acids<\/td>\n30<\/td>\n<\/tr>\n
        DAC functional group<\/td>\nMaleimidopropionic acid (MPA)<\/td>\n<\/tr>\n
        Solubility<\/td>\nSoluble in water<\/td>\n<\/tr>\n
        Form<\/td>\nFreeze-dried powder (white)<\/td>\n<\/tr>\n
        pi<\/td>\n~9.5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
        Structure of the MPA Group<\/strong><\/h3>\n
        The maleimidopropionic group (MPA) consists of:<\/p>\n
          \n
        • Maleimide ring (reactive group)<\/li>\n
        • Propionic chain (spacer)<\/li>\n
        • Amide bond with the \u03b5-amino group of lysine<\/li>\n<\/ul>\n
          Purity, identification and quality control<\/strong><\/h2>\n
          Product Specification ONE CJC-1295 WITH DAC 5 mg<\/strong><\/h3>\n
          Quality parameters:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
          Test<\/th>\nMethod<\/th>\nSpecification<\/th>\n<\/tr>\n<\/thead>\n
          Cleanliness<\/td>\nHPLC<\/td>\n\u226598%<\/td>\n<\/tr>\n
          Identification<\/td>\nMS<\/td>\nConsistent with theoretical mass<\/td>\n<\/tr>\n
          Water content<\/td>\nKarl Fischer<\/td>\n\u22648%<\/td>\n<\/tr>\n
          Acetate content<\/td>\nTitration<\/td>\n\u226412%<\/td>\n<\/tr>\n
          MPA group activity<\/td>\nCysteine \u200b\u200btest<\/td>\nReactive<\/td>\n<\/tr>\n
          Appearance<\/td>\nVisual<\/td>\nWhite lyophilisate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
          DAC Group Quality Control<\/strong><\/h3>\n
          Specific tests for mold with DAC:<\/p>\n
            \n
          • Verification of the presence of a maleimide group<\/li>\n
          • Reactivity test with model thiols<\/li>\n
          • Purity analysis including MPA hydrolysates<\/li>\n<\/ul>\n
            Storage and laboratory handling<\/strong><\/h2>\n
            Storage Conditions<\/strong><\/h3>\n
            ATTENTION:<\/strong> The maleimide group is sensitive to moisture and may undergo hydrolysis.<\/p>\n
            Freeze-dried form (unopened):<\/strong>
            \n– Optimum temperature: -20\u00b0C (required)
            \n– Protect especially against moisture
            \n– Store in a dry atmosphere (silica gel)
            \n– Shelf life: 18-24 months at -20\u00b0C<\/p>\n
            After reconstitution:<\/strong>
            \n– Solvent: sterile water, pH 6-7
            \n– Use or freeze immediately
            \n– Refrigerator storage: max. 48-72 hours
            \n– Avoid pH >7 (maleimide hydrolysis)<\/p>\n
            Special Precautions<\/strong><\/h3>\n
            Due to the reactive MPA group:<\/p>\n
              \n
            • Avoid contact with substances containing thiol groups<\/li>\n
            • Do not use buffers containing DTT or \u03b2-mercaptoethanol<\/li>\n
            • Work quickly after reconstitution<\/li>\n
            • Monitor the stability of the reactive group<\/li>\n<\/ul>\n
              Mechanism of action at the molecular level<\/strong><\/h2>\n
              Two-phase Mechanism of Action<\/strong><\/h3>\n
              CJC-1295 with DAC exhibits a unique two-phase mechanism in research models:<\/p>\n
              Phase 1: Binding to albumin<\/strong>
              \n– The maleimide group reacts with Cys-34 of albumin
              \n– Formation of a covalent thioester bond
              \n– Formation of a peptide-albumin complex (~70 kDa)<\/p>\n
              Phase 2: Receptor interaction<\/strong>
              \n– The bound peptide retains the ability to bind GHRH-R
              \n– Albumin serves as a carrier and stabilizing factor
              \n– Slow dissociation ensures prolonged action<\/p>\n
              In Vitro Studies on the DAC Complex<\/strong><\/h3>\n
              Laboratory tests analyze:<\/p>\n
              Kinetics of binding to albumin:<\/strong>
              \n– Reaction rate with cysteine-34 HSA
              \n– Stability of the resulting bond
              \n– The influence of conditions on the efficiency of conjugation<\/p>\n
              Biological activity of the complex:<\/strong>
              \n– Preservation of GHRH-R binding capacity
              \n– Comparison with free peptide
              \n– The influence of albumin on conformation<\/p>\n
              GHRH receptor (GHRH-R)<\/strong><\/h3>\n
              In vitro studies on the GHRH receptor include:<\/p>\n
                \n
              • Competitive binding tests<\/li>\n
              • Activation of the cAMP pathway<\/li>\n
              • Comparison of free and albumin-bound forms<\/li>\n<\/ul>\n
                Applications in Scientific Research<\/strong><\/h2>\n
                Research on Conjugation Technology<\/strong><\/h3>\n
                CJC-1295 with DAC is a model example of technology for extending the action of peptides:<\/p>\n
                  \n
                • Optimization of reactive groups<\/li>\n
                • Research on the connection site<\/li>\n
                • The influence of conjugation on activity<\/li>\n<\/ul>\n
                  In Vitro Pharmacokinetic Studies<\/strong><\/h3>\n
                    \n
                  • Modeling binding to albumin<\/li>\n
                  • Stability of the complex under physiological conditions<\/li>\n
                  • Release of the peptide from the complex<\/li>\n<\/ul>\n
                    Comparative Research<\/strong><\/h3>\n
                      \n
                    • CJC-1295 with DAC vs. without DAC<\/li>\n
                    • Comparison with other life extension technologies<\/li>\n
                    • Assessment of the impact of conjugation on selectivity<\/li>\n<\/ul>\n
                      Development of Analytical Methods<\/strong><\/h3>\n
                        \n
                      • Methods for determining the peptide-albumin complex<\/li>\n
                      • Techniques for distinguishing free and bound forms<\/li>\n
                      • Validation of stability tests<\/li>\n<\/ul>\n
                        Reservations<\/strong><\/h3>\n
                        IMPORTANT:<\/strong> The product is intended for in vitro testing only. Not intended for:
                        \n– Use in humans or animals
                        \n– Diagnostic or therapeutic purposes
                        \n– Production of pharmaceutical preparations<\/p>\n
                        Summary<\/strong><\/h2>\n
                        CJC-1295 with DAC is an advanced GHRH analogue equipped with a maleimidopropionic group enabling covalent binding to albumin. This innovative modification makes it a valuable tool in research on technologies for extending the action of peptides and the pharmacokinetics of macromolecules.<\/p>\n
                        Material One Peptides CJC-1295 WITH DAC 5 mg offers:<\/p>\n
                          \n
                        • High purity \u226598% HPLC<\/li>\n
                        • An active, verified MPA group<\/li>\n
                        • Stable freeze-dried form<\/li>\n
                        • Full analytical documentation<\/li>\n<\/ul>\n
                          Science FAQ<\/strong><\/h2>\n
                          1. What does DAC mean in the name CJC-1295 with DAC?<\/strong><\/h3>\n
                          DAC is an abbreviation for Drug Affinity Complex – a technology developed by ConjuChem Biotechnologies. It involves the attachment of a maleimidopropionic group (MPA) to the peptide, which reacts with free thiol groups (mainly Cys-34) in plasma albumins, forming a covalent complex. In research models, this leads to a significant increase in the half-life of the peptide.<\/p>\n
                          2. How to store CJC-1295 with DAC?<\/strong><\/h3>\n
                          Due to the reactive maleimide group, CJC-1295 from DAC requires special storage conditions. The lyophilisate should be stored at -20\u00b0C, protected from moisture (silica gel recommended). After reconstitution, use immediately or freeze – refrigerated storage should not exceed 48-72 hours. Avoid pH >7 and contact with reducing agents.<\/p>\n
                          3. What is the difference between the CJC-1295 with DAC and the version without DAC?<\/strong><\/h3>\n
                          The main differences are: the number of amino acids (30 vs. 29), the presence of an MPA group at the C-terminus, the ability to covalently bind to albumin and the half-life in research models (~8 days vs. ~30 min). The DAC version has a higher molar mass (~3647 vs. ~3368 g\/mol) and requires more stringent storage conditions.<\/p>\n
                          4. What research is CJC-1295 with DAC used for?<\/strong><\/h3>\n
                          The peptide is used in in vitro studies regarding: peptide-protein conjugation technology, pharmacokinetics of peptide-albumin complexes, optimization of prolonged release, GHRH receptor studies and the development of analytical methods for conjugates. It is not intended for use on humans or animals.<\/p>\n
                          5. How to check the activity of an MPA group?<\/strong><\/h3>\n
                          The activity of the maleimide group can be verified in a simple test with a model thiol (e.g. cysteine, glutathione). The active MPA group reacts with thiol, which can be detected by spectrophotometric or chromatographic methods. The lack of reaction indicates hydrolysis of the maleimide group.<\/p>\n
                          The most important research conclusions<\/strong><\/h2>\n
                          The most important features of the product ONE CJC-1295 WITH DAC 5 mg:<\/strong><\/p>\n
                            \n
                          • Technology<\/strong> \u2013 Drug Affinity Complex (DAC)<\/li>\n
                          • Reactive group<\/strong> \u2013 maleimidopropionic acid (MPA)<\/li>\n
                          • Molar mass<\/strong> \u2013 ~3647 g\/mol<\/li>\n
                          • Number of amino acids<\/strong> \u2013 30<\/li>\n
                          • Cleanliness<\/strong> \u2013 minimum 98% HPLC<\/li>\n
                          • Binding to albumin<\/strong> \u2013 covalent via Cys-34<\/li>\n
                          • Storage<\/strong> \u2013 -20\u00b0C, protect from moisture<\/li>\n
                          • Destiny<\/strong> \u2013 only in vitro tests<\/li>\n<\/ul>\n
                            \n
                            Bibliography<\/h3>\n
                              \n
                            1. Teichman SL, et al. (2006)<\/strong> “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults” – Journal of Clinical Endocrinology & Metabolism, 91(3):799-805.
                              \nLink: https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/<\/li>\n
                            2. Ionescu M, Bhopale VM, et al. (2006)<\/strong> “Pituitary and metabolic effects of a GHRH analogue with prolonged duration of action” – Journal of Clinical Endocrinology & Metabolism, 91(11):4603-4610.
                              \nLink: https:\/\/pubmed.ncbi.nlm.nih.gov\/16954156\/<\/li>\n
                            3. Jett\u00e9 L, et al. (2005)<\/strong> “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog” – Endocrinology, 146(7):3052-3058.
                              \nLink: https:\/\/pubmed.ncbi.nlm.nih.gov\/15817670\/<\/li>\n<\/ol>\n<\/section>\n
                              \n
                              Chemical data source<\/h3>\n
                                \n
                              • PubChem. CJC-1295, CID 91971820<\/cite><\/a>.<\/li>\n<\/ul>\n<\/section>\n
                                Variant comparison:<\/strong> see the overview CJC-1295 variants in research<\/a> in the context of laboratory research and RUO framing.<\/p>\n